Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Primary Care
When advising patients on starting Avacopan for Granulomatosis with polyangiitis, what side effects do you tell patients are commonly seen in clinical practice?
Related Questions
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
Do you still consider the use of pegloticase in someone with substantial tophaceous burden despite optimal uric acid levels?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
When do you obtain nerve biopsy to evaluate for vasculitic neuropathy in patients with distal symmetric polyneuropathies?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
